Evaxion A/S

Greetings and welcome to Elaxian Biotech first quarter 2022 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Kovic Davis of Lifesize Advisors. Please go ahead, sir.

Thanks, Peter. Hello, everyone, and thanks for joining us. I'd like to remind everyone that the following discussion contains certain statements that are considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Because forward-looking statements involve risks and uncertainties, they are not guarantees of future performance, and actual results may differ materially. from those expressed or implied by these forward-looking statements due to a variety of factors, including those risk factors discussed in the company's prospectus filed on November 5th, 2021, and the company's current and future reports filed with or submitted to the Securities and Exchange Commission. At this time, I'd like to turn the conference call over to Lars Wigner, the company's president and CEO. Please go ahead, Lars.

Thank you, Corey, and good morning to everyone. So thank you for joining us for this Evaction Biotech Q1 earnings call. I'm Lars Wigner, Chief Executive Officer of Evaction. With me today is Evaction's Chief Operating Officer Jesper Nygaard Nissen, who is currently Interim Chief Financial Officer. We'll give you a short presentation on our business and results and then open the call for your questions. Let me begin by saying EVACTION continues exciting clinical momentum in the first quarter of 2022, progressing our lead cancer therapy towards a new Phase IIb clinical trial. The upcoming trial will combine EVX01 with MERS-Ketruda for treatment of patients with metastatic melanoma, a condition for which there is significant unmet medical need. We also completed recruitment for the Phase 1-2A clinical trial for our second cancer therapy, EVXO2. And we are advancing this product candidate into a dedicated Phase 2B clinical trial in patients with resectable melanoma. We believe that these are significant steps forward for Evaction in our pursuit to use our existing pipeline of cancer therapies to improve the treatment landscape in melanoma and possible other cancers as well. We are also actively discussing potential partnerships with pharmaceutical and biotech companies, and we are optimistic about achieving solid progress on this during 2022. In January 2022, we received regulatory clearance to initiate our Phase IIb trial of EVX01 with Merck's Gertrude. We plan to have the first patient first visit for EVX01 in the first half of 2022. Also in January 2022, we completed recruitment for our Phase I-IIa clinical trial for EVX02, advancing into a dedicated Phase IIb clinical adjuvant trial in patients with resectable melanoma. We plan to file for regulatory clearance in patients with resectable melanoma by the first half of 2022 and have first patient first visit in by the second half of 2022. The EVX 01, 02, and 03 products all come from our pioneer AI platform, which generate patient-specific cancer immune therapies. We believe that our AI models allow us to identify unique drug targets, which may translate into a higher likelihood of clinical success. We are also progressing on our lead candidate on the EDEN platform, which generate vaccines against bacteria diseases. The program EVX B1 is a vaccine for the prevention of staph aureus in skin and soft tissue infections. We also plan to select our second bacteria product candidate in the second half of 2022. Furthermore, we plan to select the first vial candidate from our Raven platform in the second half of 2022. Outside of the clinic, we announced publications on personalized therapy with EVX01 in patients with metastatic melanoma in the open-access peer-reviewed medical science journal Oncoimmunology. Evaction also hosted a key opinion leader webinar, which acclaimed experts on metastatic melanoma and personalized cancer immunotherapies. This concludes our business and operation update for Q1 2022. I will now turn the call over to Jesper for our first quarter 2022 financial review.